Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.
Identifieur interne : 000509 ( Main/Exploration ); précédent : 000508; suivant : 000510Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.
Auteurs : Zaid Abassi [Israël] ; Suheir Assady [Israël] ; Emad E. Khoury [Israël] ; Samuel N. Heyman [Israël]Source :
- American journal of physiology. Heart and circulatory physiology [ 1522-1539 ] ; 2020.
Descripteurs français
- KwdFr :
- Humains, Infections à coronavirus (), Infections à coronavirus (enzymologie), Infections à coronavirus (métabolisme), Infections à coronavirus (virologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (administration et posologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (effets indésirables), Maladies cardiovasculaires (enzymologie), Maladies cardiovasculaires (virologie), Myocarde (enzymologie), Myocarde (métabolisme), Pandémies, Peptidyl-Dipeptidase A (biosynthèse), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (), Pneumopathie virale (enzymologie), Pneumopathie virale (métabolisme), Pneumopathie virale (virologie).
- MESH :
- administration et posologie : Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- biosynthèse : Peptidyl-Dipeptidase A.
- effets indésirables : Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- enzymologie : Infections à coronavirus, Maladies cardiovasculaires, Myocarde, Pneumopathie virale.
- métabolisme : Infections à coronavirus, Myocarde, Peptidyl-Dipeptidase A, Pneumopathie virale.
- virologie : Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- Humains, Infections à coronavirus, Pandémies, Pneumopathie virale.
English descriptors
- KwdEn :
- Angiotensin-Converting Enzyme Inhibitors (administration & dosage), Angiotensin-Converting Enzyme Inhibitors (adverse effects), Betacoronavirus (metabolism), Cardiovascular Diseases (enzymology), Cardiovascular Diseases (virology), Coronavirus Infections (complications), Coronavirus Infections (enzymology), Coronavirus Infections (metabolism), Coronavirus Infections (virology), Humans, Myocardium (enzymology), Myocardium (metabolism), Pandemics, Peptidyl-Dipeptidase A (biosynthesis), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (complications), Pneumonia, Viral (enzymology), Pneumonia, Viral (metabolism), Pneumonia, Viral (virology).
- MESH :
- chemical , administration & dosage : Angiotensin-Converting Enzyme Inhibitors.
- chemical , adverse effects : Angiotensin-Converting Enzyme Inhibitors.
- chemical , biosynthesis : Peptidyl-Dipeptidase A.
- complications : Coronavirus Infections, Pneumonia, Viral.
- enzymology : Cardiovascular Diseases, Coronavirus Infections, Myocardium, Pneumonia, Viral.
- metabolism : Betacoronavirus, Coronavirus Infections, Myocardium, Peptidyl-Dipeptidase A, Pneumonia, Viral.
- virology : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- Humans, Pandemics.
DOI: 10.1152/ajpheart.00215.2020
PubMed: 32223552
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000475
- to stream PubMed, to step Curation: 000475
- to stream PubMed, to step Checkpoint: 000407
- to stream Ncbi, to step Merge: 003598
- to stream Ncbi, to step Curation: 003598
- to stream Ncbi, to step Checkpoint: 003598
- to stream Main, to step Merge: 000509
- to stream Main, to step Curation: 000509
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.</title><author><name sortKey="Abassi, Zaid" sort="Abassi, Zaid" uniqKey="Abassi Z" first="Zaid" last="Abassi">Zaid Abassi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Assady, Suheir" sort="Assady, Suheir" uniqKey="Assady S" first="Suheir" last="Assady">Suheir Assady</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nephrology and Hypertension, Rambam Health Care Campus, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Nephrology and Hypertension, Rambam Health Care Campus, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Khoury, Emad E" sort="Khoury, Emad E" uniqKey="Khoury E" first="Emad E" last="Khoury">Emad E. Khoury</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Heyman, Samuel N" sort="Heyman, Samuel N" uniqKey="Heyman S" first="Samuel N" last="Heyman">Samuel N. Heyman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Hadassah Hebrew University Hospital, Mount Scopus, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Medicine, Hadassah Hebrew University Hospital, Mount Scopus, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32223552</idno><idno type="pmid">32223552</idno><idno type="doi">10.1152/ajpheart.00215.2020</idno><idno type="wicri:Area/PubMed/Corpus">000475</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000475</idno><idno type="wicri:Area/PubMed/Curation">000475</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000475</idno><idno type="wicri:Area/PubMed/Checkpoint">000407</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000407</idno><idno type="wicri:Area/Ncbi/Merge">003598</idno><idno type="wicri:Area/Ncbi/Curation">003598</idno><idno type="wicri:Area/Ncbi/Checkpoint">003598</idno><idno type="wicri:Area/Main/Merge">000509</idno><idno type="wicri:Area/Main/Curation">000509</idno><idno type="wicri:Area/Main/Exploration">000509</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.</title><author><name sortKey="Abassi, Zaid" sort="Abassi, Zaid" uniqKey="Abassi Z" first="Zaid" last="Abassi">Zaid Abassi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Assady, Suheir" sort="Assady, Suheir" uniqKey="Assady S" first="Suheir" last="Assady">Suheir Assady</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nephrology and Hypertension, Rambam Health Care Campus, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Nephrology and Hypertension, Rambam Health Care Campus, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Khoury, Emad E" sort="Khoury, Emad E" uniqKey="Khoury E" first="Emad E" last="Khoury">Emad E. Khoury</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Heyman, Samuel N" sort="Heyman, Samuel N" uniqKey="Heyman S" first="Samuel N" last="Heyman">Samuel N. Heyman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Hadassah Hebrew University Hospital, Mount Scopus, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Medicine, Hadassah Hebrew University Hospital, Mount Scopus, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author></analytic><series><title level="j">American journal of physiology. Heart and circulatory physiology</title><idno type="eISSN">1522-1539</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors (administration & dosage)</term><term>Angiotensin-Converting Enzyme Inhibitors (adverse effects)</term><term>Betacoronavirus (metabolism)</term><term>Cardiovascular Diseases (enzymology)</term><term>Cardiovascular Diseases (virology)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (enzymology)</term><term>Coronavirus Infections (metabolism)</term><term>Coronavirus Infections (virology)</term><term>Humans</term><term>Myocardium (enzymology)</term><term>Myocardium (metabolism)</term><term>Pandemics</term><term>Peptidyl-Dipeptidase A (biosynthesis)</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (enzymology)</term><term>Pneumonia, Viral (metabolism)</term><term>Pneumonia, Viral (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (enzymologie)</term><term>Infections à coronavirus (métabolisme)</term><term>Infections à coronavirus (virologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (administration et posologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (effets indésirables)</term><term>Maladies cardiovasculaires (enzymologie)</term><term>Maladies cardiovasculaires (virologie)</term><term>Myocarde (enzymologie)</term><term>Myocarde (métabolisme)</term><term>Pandémies</term><term>Peptidyl-Dipeptidase A (biosynthèse)</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (enzymologie)</term><term>Pneumopathie virale (métabolisme)</term><term>Pneumopathie virale (virologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Myocarde</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Myocardium</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Myocardium</term><term>Peptidyl-Dipeptidase A</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Myocarde</term><term>Peptidyl-Dipeptidase A</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term></keywords></textClass></profileDesc></teiHeader></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Abassi, Zaid" sort="Abassi, Zaid" uniqKey="Abassi Z" first="Zaid" last="Abassi">Zaid Abassi</name></noRegion><name sortKey="Assady, Suheir" sort="Assady, Suheir" uniqKey="Assady S" first="Suheir" last="Assady">Suheir Assady</name><name sortKey="Heyman, Samuel N" sort="Heyman, Samuel N" uniqKey="Heyman S" first="Samuel N" last="Heyman">Samuel N. Heyman</name><name sortKey="Khoury, Emad E" sort="Khoury, Emad E" uniqKey="Khoury E" first="Emad E" last="Khoury">Emad E. Khoury</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000509 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000509 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32223552
|texte= Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32223552" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |